Hyloris Teams Up With Vaneltix For Value-Added Interstitial Cystitis Pain Treatment
Results From Phase II Trials For Lidocaine/Heparin Candidate Could Be Ready By Late 2023
Hyloris will make payments of up to $6.7m to Vaneltix, alongside a $500,000 loan, to support their collaboration to develop and commercialize Alenura, a first-line drug treatment for acute pain caused by interstitial cystitis that combines lidocaine and heparin.
